Target intelligence / Profile preview

Vesicle-associated membrane protein 1 and 2 (VAMP1/2)

Target
VAMP1/2
Molecular classification
SNARE protein, v-SNARE, R-SNARE, Type IV membrane protein, Integral membrane protein
01

Overview

Vesicle-associated membrane protein 1 (VAMP1) and 2 (VAMP2), also known as synaptobrevin 1 and 2, are essential v-SNARE proteins located on the membranes of synaptic vesicles [1, 2]. They play a critical role in the molecular machinery of exocytosis by pairing with t-SNAREs (SNAP-25 and Syntaxin-1) on the presynaptic plasma membrane to form the SNARE complex, which drives membrane fusion and neurotransmitter release [4, 8]. VAMP1 is predominantly expressed in the spinal cord and motor neurons, while VAMP2 is the major isoform in the brain and is involved in fast, calcium-triggered synaptic transmission [11, 19]. These proteins are the primary targets of several clostridial neurotoxins, most notably Botulinum toxin type B and Tetanus toxin, which cleave VAMP at specific sites to block neurotransmission [13, 15]. Clinically, drugs like RimabotulinumtoxinB exploit this mechanism to treat conditions characterized by muscle overactivity, such as cervical dystonia [10, 15]. Beyond their role as toxin targets, VAMP proteins are being investigated as biomarkers for synaptic degeneration in neurodegenerative diseases like Alzheimer's [5, 20].

Other names
Synaptobrevin 1Synaptobrevin 2SYB1SYB2VAMP-1VAMP-2R-SNAREv-SNARE
02

Mechanism of action

Zinc-dependent proteolytic cleavage of VAMP proteins by the toxin's light chain, which prevents the assembly of the functional SNARE complex and subsequently blocks the exocytosis of neurotransmitters [13, 15].

03

Biological functions

Neurotransmitter releaseVesicle dockingMembrane fusionExocytosisSynaptic vesicle recyclingGLUT4 translocation
04

Disease associations

BotulismTetanusCervical dystoniaSpasticityNeurodevelopmental disordersAlzheimer's diseaseEpilepsy
05

Safety considerations

Distant spread of toxin effectRespiratory failureSevere muscle weaknessImmunogenicity (neutralizing antibodies)
06

Interacting drugs

RimabotulinumtoxinB

4 more in the full profile.

07

Biomarkers

Cerebrospinal fluid VAMP2 levelsCleaved VAMP fragmentsMuscle paralysis/weakness

Beyond the preview

Go deeper on Vesicle-associated membrane protein 1 and 2 (VAMP1/2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vesicle-associated membrane protein 1 and 2 (VAMP1/2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call